Insights from CARTITUDE-4 and KarMMa-3 in R/R MM

Opinion
Video

Experts on multiple myeloma provide their impressions of the CARTITUDE-4 and KarMMa-3 studies, which led to the approval of cilta-cel and ide-cel in earlier lines of treatment for patients with relapsed/refractory disease.

Video content above is prompted by the following questions:

  • Briefly review the CARTITUDE-4 trial that led to cilta-cel’s approval in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM).
    • Please comment on the patient population – intention-to-treat vs patients treated.
    • What was the rationale for the difference? How does it affect your interpretation of the data?
    • How did the safety outcomes compare with other CARTITUDE trials?
    • Please share your real-world experience.
  • Please review data from KarMMa-3, which led to ide-cel’s approval in earlier lines of therapy for R/R MM.
    • What are thoughts on the efficacy and safety outcomes?
    • Please share your real-world experience. 
  • How do these approvals impact the current and future treatment landscape of R/R MM?
    • How might you choose one over the other?
    • How does it address an unmet need?
Recent Videos
4 experts in this video
4 experts in this video
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Related Content